Supplemental Table 2.
SARS-CoV-2–specific antibody titer correlation with composite participant symptom score after vaccine dose 2
| V2 time point antibodies (2–6 wk after vaccination) | ||
|---|---|---|
| Spearman rho | P value | |
| Maternal serum | ||
| Spike IgG1 | 0.25 | .05 |
| Spike IgG3 | 0.45 | .0003 |
| RBD IgG1 | 0.29 | .02 |
| RBD IgG3 | 0.36 | .005 |
| Breastmilk | ||
| Spike IgG1 | 0.49 | .04 |
| Spike IgG3 | 0.42 | .04 |
| Spike IgA | 0.42 | .04 |
| RBD IgG1 | 0.42 | .04 |
Ig, immunoglobulin; RBD, receptor-binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus.
Gray et al. Coronavirus disease 2019 vaccination in pregnancy and lactation. Am J Obstet Gynecol 2021.